Boehringer Ingelheim executives are very positive about the continued success of the company throughout 2007 and are confident about the future. Boehringer Ingelheim, Germany’s second largest pharmaceutical company, enjoyed continued success in 2007 and its growth is outpacing the pharmaceuticals market for the eighth year in a row. A host of compounds in the pipeline means that the company can afford to feel confident about the near future. At a press conference given by the family-run company it was once again clear that its managers are given the scope and time for medium-term planning.
Professor Muff highlighted the very solid financial figures. Despite losses of EUR 1 billion, in particular in the US generics business involving Flomax®, current and future products stand to achieve sales of up to EUR 2.5 billion. Andreas Barner from R&D only foresees a slight dent in the results and has a positive outlook regarding the competition from Aventis who have plans to launch a product to compete with Pradaxa.